Chiesi’s Dual Engine: Growth Fueled by Innovation and Impact

PARMA, Italy – September 09, 2026 – At first glance, Chiesi Group’s half-year financial report reads like a textbook case of steady corporate execution. The Italian biopharmaceutical firm posted revenues of €1.89 billion, a respectable 3.6% increase at constant exchange rates, with a healthy EBITDA margin of 29.4%. But to stop at these headline figures is to miss the more compelling story. Beneath the surface of solid growth lies a meticulously engineered strategy that weds aggressive, targeted expansion with a deeply embedded commitment to social and environmental value. The company’s performance isn’t just about what it earned; it’s about how it’s building a resilient, multi-faceted enterprise where innovation, acquisition, and impact are not competing priorities, but a single, integrated engine for growth.

The KalVista Gambit: A Catalyst for U.S. and Rare Disease Dominance

The most significant driver of Chiesi’s strategic direction is its recent acquisition of KalVista Pharmaceuticals, a move that redefines its footprint in both the rare disease space and the crucial U.S. market. The deal, valued at approximately $1.9 billion, represents Chiesi’s largest acquisition to date and was executed at a 36% premium over KalVista's 30-day average share price, signaling a high-conviction bet. This wasn't a tentative step but a decisive leap to capture a key asset: Ekterly (sebetralstat), a first-in-class oral, on-demand treatment for hereditary angioedema (HAE) attacks.

The strategic importance of Ekterly cannot be overstated. Approved by the FDA in July 2025, it addresses a significant unmet need for patients who previously relied on injectable therapies. Its successful launch, generating $49 million in its first year, provides Chiesi with a powerful new revenue stream in a market projected to grow to over $6.6 billion by 2033. This acquisition directly fuels the growth seen in the H1 report, where the rare diseases unit expanded by 9.9% and the U.S. market surged by 9.6%. It's a clear example of execution aligning with strategy, using a major capital investment to bolster a high-growth therapeutic area and significantly expand commercial infrastructure in the world’s largest pharmaceutical market.

The R&D Dividend: Investing 22.5% of Revenue in Future Cures

While strategic acquisitions provide immediate growth, Chiesi’s long-term vision is anchored by its formidable commitment to internal innovation. The company invested a staggering €426 million in Research & Development in the first half of 2026 alone, a figure representing 22.5% of its total revenues. This R&D-to-revenue ratio is notably high, indicating a corporate philosophy that prioritizes the long, arduous path of scientific discovery over short-term margin optimization.

This investment is not an undifferentiated spend. It is sharply focused on advancing the pipeline across the company’s core pillars. In respiratory health, efforts are directed toward multi-modal inhalers and the advanced "Triple programme," a single-inhaler therapy with three active ingredients. In rare diseases, the pipeline extends beyond HAE to include targeted enzyme replacement therapies for lysosomal storage disorders. The specialty care unit continues to build on its legacy in neonatology, where its product Curosurf has been a standard of care for neonatal respiratory distress syndrome. This disciplined allocation of capital ensures that Chiesi is not just spending on research, but investing in specific solutions for areas of high unmet medical need, building a sustainable pipeline that will fuel growth for years to come.

Engineering Sustainability: The Carbon Minimal Inhaler Goes to Market

Perhaps the most tangible evidence of Chiesi’s B Corp ethos in action is its Carbon Minimal Inhaler (CMI) platform. This initiative moves beyond corporate sustainability reports and into the realm of product re-engineering. The program is transitioning the company’s entire portfolio of pressurized metered-dose inhalers (pMDIs) to a new propellant, HFA-152a, which has a low global warming potential. The result is a projected 90% reduction in the carbon footprint for these life-saving devices, a critical step toward the company’s goal of achieving Net-Zero greenhouse gas emissions by 2035.

This is not a distant ambition but a present-day reality. In July 2026, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Chiesi’s first CMI product, a beclometasone pMDI, marking a major regulatory milestone. Further submissions are already validated in Europe. To ensure this innovation reaches patients at scale, Chiesi has expanded its strategic partnership with inhalation specialist Bespak to increase manufacturing capacity. This demonstrates a mastery of execution, connecting an ambitious environmental goal with the complex industrial and regulatory logistics required to bring a next-generation medical product to market without disrupting patient care.

Quantifying the Impact: A €6 Billion Economic Footprint

Chiesi is actively working to quantify its value beyond the balance sheet, a mandate central to its identity as a certified B Corp. A recent Economic Footprint assessment conducted with PwC Italy provides a compelling look at this broader contribution. According to the 2025 study, the Group generated approximately €6 billion in total GDP worldwide, supported over 56,000 jobs, and contributed nearly €2 billion in taxes and public revenues. With deep roots in Europe, the region accounted for €4.1 billion of that GDP impact and nearly 30,000 jobs.

This data provides a powerful counter-narrative to the often-narrow view of corporate value. As stated by Jean Marc Bellemin, CFO and Interim CEO of Chiesi Group, the focus is on combining "sustainable growth with continued innovation and long-term value creation for patients and society.” The report illustrates this commitment in concrete terms, demonstrating how investment in R&D hubs, supplier networks, and commercial operations creates a ripple effect that strengthens local economies. By measuring and reporting this impact, Chiesi is not only holding itself accountable to its B Corp charter but is also setting a new standard for how a global biopharmaceutical company can define and deliver success.